Skip to main content
Erschienen in: Surgical Endoscopy 1/2018

22.06.2017

Scintigraphic peritoneography reveals a non-uniform 99mTc-Pertechnetat aerosol distribution pattern for Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) in a swine model

verfasst von: Alexander Bellendorf, Veria Khosrawipour, Tanja Khosrawipour, Simon Siebigteroth, Joseph Cohnen, David Diaz-Carballo, Andreas Bockisch, Jürgen Zieren, Urs Giger-Pabst

Erschienen in: Surgical Endoscopy | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Although recent data are contradictory, it is still claimed that Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) would deliver an aerosol which distributes homogeneously throughout the entire abdominal cavity.

Methods

99mTc-Pertechnetat was administered in four postmortem swine using either PIPAC or liquid intra-peritoneal chemotherapy (IPC). The animals were examined by planar scintigraphy and SPECT/CT. Planar distribution images were divided into four regions of interest (ROIs: right/left upper and lower abdominal quadrant). SPECT/CT slices were scanned for areas of intense nuclide accumulation (“hot spots”). The percentage of relative distribution for planar scintigraphy was calculated by dividing the summed individual counts of each ROI by total counts measured in the entire abdominal cavity. The relative distribution of the “hot spots” was analyzed by dividing the counts of the local volume of interest (VOI) by the summed volume counts measured in the entire abdominal cavity.

Results

In all four animals, planar scintigraphy showed inhomogeneous nuclide distribution. After PIPAC only 8–10% of the delivered nuclide was detected in one ROI with a mean deviation of 40% and 74% from a uniform nuclide distribution pattern. In all animals, SPECT/CT revealed “hot spots” beneath the PIPAC Micropump, catheter tip, and in the cul-de-sac region which comprise about 25% of the total amount of delivered nuclide in 2.5% of the volume of the entire abdominal cavity.

Conclusions

Our present data indicate that the intra-abdominal aerosol distribution pattern of PIPAC therapy is non-homogeneous and that the currently applied technology has still not overcome the problem of inhomogeneous drug distribution of IPC.
Literatur
1.
Zurück zum Zitat Solass W, Hetzel A, Nadiradze G, Sagynaliev E, Reymond MA (2012) Description of a novel approach for intraperitoneal drug delivery and the related device. Surg Endosc 26:1849–1855CrossRefPubMed Solass W, Hetzel A, Nadiradze G, Sagynaliev E, Reymond MA (2012) Description of a novel approach for intraperitoneal drug delivery and the related device. Surg Endosc 26:1849–1855CrossRefPubMed
2.
Zurück zum Zitat Solass W, Kerb R, Mürdter T, Giger-Pabst U, Strumberg D, Tempfer C, Zieren J, Schwab M, Reymond MA (2014) Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol 21:553–559CrossRefPubMed Solass W, Kerb R, Mürdter T, Giger-Pabst U, Strumberg D, Tempfer C, Zieren J, Schwab M, Reymond MA (2014) Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol 21:553–559CrossRefPubMed
3.
Zurück zum Zitat Göhler D, Khosrawipour V, Khosrawipour T, Diaz-Carballo D, Falkenstein TA, Zieren J, Stintz M, Giger-Pabst U (2016) Technical description of the microinjection pump (MIP®) and granulometric characterization of the aerosol applied for pressurized intraperitoneal aerosol chemotherapy (PIPAC). Surg Endosc 31(4):1778–1784. doi:10.1007/s00464-016-5174-5 CrossRefPubMed Göhler D, Khosrawipour V, Khosrawipour T, Diaz-Carballo D, Falkenstein TA, Zieren J, Stintz M, Giger-Pabst U (2016) Technical description of the microinjection pump (MIP®) and granulometric characterization of the aerosol applied for pressurized intraperitoneal aerosol chemotherapy (PIPAC). Surg Endosc 31(4):1778–1784. doi:10.​1007/​s00464-016-5174-5 CrossRefPubMed
4.
Zurück zum Zitat Dedrick RL, Flessner MF (1997) Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J Natl Cancer Inst 89(7):480–487CrossRefPubMed Dedrick RL, Flessner MF (1997) Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J Natl Cancer Inst 89(7):480–487CrossRefPubMed
5.
Zurück zum Zitat Kakchekeeva T, Demtröder C, Herath NI, Griffiths D, Torkington J, Solaß W, Dutreix M, Reymond MA (2016) In vivo feasibility of electrostatic precipitation as an adjunct to pressurized intraperitoneal aerosol chemotherapy (ePIPAC). Ann Surg Oncol 23:592–598CrossRefPubMedPubMedCentral Kakchekeeva T, Demtröder C, Herath NI, Griffiths D, Torkington J, Solaß W, Dutreix M, Reymond MA (2016) In vivo feasibility of electrostatic precipitation as an adjunct to pressurized intraperitoneal aerosol chemotherapy (ePIPAC). Ann Surg Oncol 23:592–598CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Khosrawipour V, Khosrawipour T, Diaz-Carballo D, Förster E, Zieren J, Giger-Pabst U (2016) Exploring the spatial drug distribution pattern during pressurized intraperitoneal aerosol chemotherapy (PIPAC). Ann Surg Oncol 23(4):1220–1224CrossRefPubMed Khosrawipour V, Khosrawipour T, Diaz-Carballo D, Förster E, Zieren J, Giger-Pabst U (2016) Exploring the spatial drug distribution pattern during pressurized intraperitoneal aerosol chemotherapy (PIPAC). Ann Surg Oncol 23(4):1220–1224CrossRefPubMed
7.
Zurück zum Zitat Khosrawipour V, Khosrawipour T, Kern AJ, Osma A, Kabakci B, Diaz-Carballo D, Förster E, Zieren J, Fakhrian K (2016) Distribution pattern and penetration depth of doxorubicin after pressurized intraperitoneal aerosol chemotherapy (PIPAC) in a postmortem swine model. J Cancer Res Clin Oncol 142(11):2275–2280. doi:10.1007/s00432-016-2234-0 CrossRefPubMed Khosrawipour V, Khosrawipour T, Kern AJ, Osma A, Kabakci B, Diaz-Carballo D, Förster E, Zieren J, Fakhrian K (2016) Distribution pattern and penetration depth of doxorubicin after pressurized intraperitoneal aerosol chemotherapy (PIPAC) in a postmortem swine model. J Cancer Res Clin Oncol 142(11):2275–2280. doi:10.​1007/​s00432-016-2234-0 CrossRefPubMed
8.
Zurück zum Zitat Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, Fontaumard E, Brachet A, Caillot JL, Faure JL, Porcheron J, Peix JL, François Y, Vignal J, Gilly FN (2000) Peritoneal carcinomatosis from non-gynecological malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 88:358–363CrossRefPubMed Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, Fontaumard E, Brachet A, Caillot JL, Faure JL, Porcheron J, Peix JL, François Y, Vignal J, Gilly FN (2000) Peritoneal carcinomatosis from non-gynecological malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 88:358–363CrossRefPubMed
9.
Zurück zum Zitat Au JL, Jang SH, Wientjes MG (2002) Clinical aspects of drug delivery to tumors. J Control Release 78:81–95CrossRefPubMed Au JL, Jang SH, Wientjes MG (2002) Clinical aspects of drug delivery to tumors. J Control Release 78:81–95CrossRefPubMed
10.
Zurück zum Zitat Shitara K, Yukis A, Tahahari D, Nakamura M, Kondo C, Tsuda T, Kii T, Tsuji Y, Utsunomiya S, Ichikawa D, Hosokawa A, Ishiguro A, Sakai D, Hironaka S, Oze I, Matsuo K, Muro K (2014) Randomized phase II study comparing dose-escalated weekly paclitaxel vs standard-dose weekly paclitaxel for patients with previously treated advanced gastric cancer. Br J Cancer 110:533–541CrossRef Shitara K, Yukis A, Tahahari D, Nakamura M, Kondo C, Tsuda T, Kii T, Tsuji Y, Utsunomiya S, Ichikawa D, Hosokawa A, Ishiguro A, Sakai D, Hironaka S, Oze I, Matsuo K, Muro K (2014) Randomized phase II study comparing dose-escalated weekly paclitaxel vs standard-dose weekly paclitaxel for patients with previously treated advanced gastric cancer. Br J Cancer 110:533–541CrossRef
11.
Zurück zum Zitat Budker VG, Monahan SD, Subbotin V (2014) Loco-regional cancer drug therapy: present approaches and rapidly reversible hydrophopization (RRH) of therapeutic agents as the future direction. Drug Disc Today 19:1855–1870CrossRef Budker VG, Monahan SD, Subbotin V (2014) Loco-regional cancer drug therapy: present approaches and rapidly reversible hydrophopization (RRH) of therapeutic agents as the future direction. Drug Disc Today 19:1855–1870CrossRef
12.
Zurück zum Zitat Dedrick RL, Myers CE, Bungay PM, DeVita VT Jr (1978) Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62:1–9PubMed Dedrick RL, Myers CE, Bungay PM, DeVita VT Jr (1978) Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62:1–9PubMed
13.
Zurück zum Zitat Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA, Gynecologic Oncology Group (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 354:34–43CrossRefPubMed Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA, Gynecologic Oncology Group (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 354:34–43CrossRefPubMed
14.
Zurück zum Zitat Elias D, Blot F, El Otmany A, Antoun S, Lasser P, Boige V, Rougier P, Ducreux M (2001) Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer 92:71–76CrossRefPubMed Elias D, Blot F, El Otmany A, Antoun S, Lasser P, Boige V, Rougier P, Ducreux M (2001) Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer 92:71–76CrossRefPubMed
15.
Zurück zum Zitat Coccolini F, Cotte E, Glehen O, Lotti M, Poiasina E, Catena F, Yonemura Y, Ansaloni L (2014) Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials. EJSO 40:12–26CrossRefPubMed Coccolini F, Cotte E, Glehen O, Lotti M, Poiasina E, Catena F, Yonemura Y, Ansaloni L (2014) Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials. EJSO 40:12–26CrossRefPubMed
16.
Zurück zum Zitat Markmann M, Walker JL (2006) Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. J Clin Oncol 24:1–7CrossRef Markmann M, Walker JL (2006) Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. J Clin Oncol 24:1–7CrossRef
17.
Zurück zum Zitat Philibert J (2005) One and a half century of diffusion: Fick, Einstein, before and beyond. Diffus Fundam 2:1–10 Philibert J (2005) One and a half century of diffusion: Fick, Einstein, before and beyond. Diffus Fundam 2:1–10
18.
Zurück zum Zitat Jacquet P, Stuart OA, Chang D, Sugarbaker PH (1996) Effects of intra-abdominal pressure on pharmacokinetics and tissue distribution of doxorubicin after intraperitoneal administration. Anticancer Drugs 7(5):569–603CrossRef Jacquet P, Stuart OA, Chang D, Sugarbaker PH (1996) Effects of intra-abdominal pressure on pharmacokinetics and tissue distribution of doxorubicin after intraperitoneal administration. Anticancer Drugs 7(5):569–603CrossRef
19.
Zurück zum Zitat Esquis P, Consolo D, Magnin G, Pointaire P, Moretto P, Ynsa MD, Beltramo JL, Drogoul C, Simonet M, Benoit L, Rat P, Chauffert B (2006) High intra-abdominal pressure enhances the penetration and antitumor effect of intraperitoneal cisplatin on experimental peritoneal carcinomatosis. Ann Surg 244(1):106–112CrossRefPubMedPubMedCentral Esquis P, Consolo D, Magnin G, Pointaire P, Moretto P, Ynsa MD, Beltramo JL, Drogoul C, Simonet M, Benoit L, Rat P, Chauffert B (2006) High intra-abdominal pressure enhances the penetration and antitumor effect of intraperitoneal cisplatin on experimental peritoneal carcinomatosis. Ann Surg 244(1):106–112CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Facy O, Al Samman S, Magnin G, Ghiringhelli F, Ladoire S, Chauffert B, Rat P, Ortega-Deballon P (2012) High pressure enhances the effect of hyperthermia in intraperitoneal chemotherapy with oxaliplatin: an experimental study. Ann Surg 256(6):1048–1088CrossRef Facy O, Al Samman S, Magnin G, Ghiringhelli F, Ladoire S, Chauffert B, Rat P, Ortega-Deballon P (2012) High pressure enhances the effect of hyperthermia in intraperitoneal chemotherapy with oxaliplatin: an experimental study. Ann Surg 256(6):1048–1088CrossRef
21.
Zurück zum Zitat Göhler D, Stintz M (2014) Granulometric characterization of airborne particulate release during spray application of nanoparticle-doped coatings. J Nanopart Res 16:1–15CrossRef Göhler D, Stintz M (2014) Granulometric characterization of airborne particulate release during spray application of nanoparticle-doped coatings. J Nanopart Res 16:1–15CrossRef
22.
Zurück zum Zitat Tempfer CB, Winnekendonk G, Solass W, Horvat R, Giger-Pabst U, Zieren J, Rezniczek GA, Reymond MA (2015) Pressurized intraperitoneal aerosol chemotherapy in women with recurrent ovarian cancer: a phase 2 study. Gynecol Oncol 137(2):223–228CrossRefPubMed Tempfer CB, Winnekendonk G, Solass W, Horvat R, Giger-Pabst U, Zieren J, Rezniczek GA, Reymond MA (2015) Pressurized intraperitoneal aerosol chemotherapy in women with recurrent ovarian cancer: a phase 2 study. Gynecol Oncol 137(2):223–228CrossRefPubMed
23.
Zurück zum Zitat Demtröder C, Solass W, Zieren J, Strumberg D, Giger-Pabst U, Reymond MA (2016) Pressurized intraperitoneal aerosol chemo-therapy with oxaliplatin in colorectal peritoneal metastasis. Colorectal Dis 18(4):364–371CrossRefPubMed Demtröder C, Solass W, Zieren J, Strumberg D, Giger-Pabst U, Reymond MA (2016) Pressurized intraperitoneal aerosol chemo-therapy with oxaliplatin in colorectal peritoneal metastasis. Colorectal Dis 18(4):364–371CrossRefPubMed
24.
Zurück zum Zitat Odendahl K, Solass W, Demtröder C, Giger-Pabst U, Zieren J, Tempfer C, Reymond MA (2015) Quality of life of patients with end-stage peritoneal metastasis treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC). Eur J Surg Oncol 41(10):1379–1385CrossRefPubMed Odendahl K, Solass W, Demtröder C, Giger-Pabst U, Zieren J, Tempfer C, Reymond MA (2015) Quality of life of patients with end-stage peritoneal metastasis treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC). Eur J Surg Oncol 41(10):1379–1385CrossRefPubMed
Metadaten
Titel
Scintigraphic peritoneography reveals a non-uniform 99mTc-Pertechnetat aerosol distribution pattern for Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) in a swine model
verfasst von
Alexander Bellendorf
Veria Khosrawipour
Tanja Khosrawipour
Simon Siebigteroth
Joseph Cohnen
David Diaz-Carballo
Andreas Bockisch
Jürgen Zieren
Urs Giger-Pabst
Publikationsdatum
22.06.2017
Verlag
Springer US
Erschienen in
Surgical Endoscopy / Ausgabe 1/2018
Print ISSN: 0930-2794
Elektronische ISSN: 1432-2218
DOI
https://doi.org/10.1007/s00464-017-5652-4

Weitere Artikel der Ausgabe 1/2018

Surgical Endoscopy 1/2018 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.